

REGENERON PHARMACEUTICALS INC

Form 8-K

February 23, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934**

**Date of Report (Date of earliest event reported):**

**February 23, 2005 (February 18, 2005)**

**REGENERON PHARMACEUTICALS, INC.**

---

**(Exact name of registrant as specified in its charter)**

**New York**

**000-19034**

**133444607**

(State or other jurisdiction of  
incorporation)

(Commission File Number)

**(I.R.S. Employer  
Identification Number)**

**777 Old Saw Mill River Road, Tarrytown, New York**

**10591-6707**

**(Address of principal executive offices)**

**(Zip Code)**

**(914) 347-7000**

---

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the

Exchange Act (17 CFR 240.14d-2(b))

- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 1.01 Entry into a Material Definitive Agreement

Item 2.02 Results of Operations and Financial Condition

Item 9.01 Financial Statements and Exhibits

Exhibit Index

EX-99.A: PRESS RELEASE

---

**Table of Contents**

**Item 1.01 Entry into a Material Definitive Agreement**

On February 18, 2005, the Company and Merck & Co., Inc. entered into Amendment No. 5 (the Fifth Amendment ) to their Manufacturing Agreement dated as of September 18, 1995 (the Manufacturing Agreement ). The Fifth Amendment was made effective as of January 1, 2005. Pursuant to the Manufacturing Agreement, the Company produces an intermediate for a Merck pediatric vaccine at the Company s Rensselaer, New York facility. The parties extended the Manufacturing Agreement through October 31, 2006 and provided Merck an opportunity, upon twelve-months prior notice, to extend the Manufacturing Agreement for an additional year through October 31, 2007. The parties also agreed to other technical amendments and modifications to the Manufacturing Agreement.

**Item 2.02 Results of Operations and Financial Condition**

On February 22, 2005, Regeneron Pharmaceuticals, Inc. announced its financial and operating results for the quarter and year ended December 31, 2004. A copy of the press release is attached hereto as Exhibit 99(a).

The information contained in the press release shall not be deemed filed for purposes of, nor shall it be deemed incorporated by reference in, any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits

99(a) Press Release of Regeneron Pharmaceuticals, Inc. dated February 22, 2005.

**Table of Contents**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS,  
INC.

Dated: February 23, 2005

By: /s/ Stuart Kolinski  
Stuart Kolinski  
Vice President and General Counsel

3

---

**Table of Contents**

**Exhibit Index**

<b>Number</b>	<b>Description</b>
99(a)	Press Release of Regeneron Pharmaceuticals, Inc. dated February 22, 2005.

4